20:59 , Aug 16, 2019 |  BioCentury  |  Emerging Company Profile

A-Alpha retools yeast mating for high throughput drug discovery

A-Alpha is co-opting yeast mating to scale up screening of candidates that create or block protein-protein interactions. The University of Washington spinout is partnering with drug developers to find biologics with defined specificity profiles, small...
00:51 , Aug 2, 2019 |  BC Extra  |  Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the...
22:14 , Jul 29, 2019 |  BC Extra  |  Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

Verastem Inc. (NASDAQ:VSTM) named board member Brian Stuglik as CEO. In June, Robert Forrester stepped down as the cancer company's president and CEO; COO Dan Paterson succeeded Forrester as president and led the executive team...
15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
23:12 , Jun 19, 2019 |  BC Extra  |  Company News

Gilead adds targeted degradation via Nurix deal in quest to strengthen growth areas

Just three months after Daniel O'Day took the helm, Gilead has pulled the trigger on adding targeted protein degradation to its modality tool kit in areas it has tagged as growth drivers. Wednesday’s announcement of...
23:09 , Jun 4, 2019 |  BC Extra  |  Company News

Arvinas adds to momentum with Bayer deal for protein degraders

Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes...
00:01 , May 11, 2019 |  BC Innovations  |  Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

A study from Arvinas founder Craig Crews is the second report in as many months of a technology geared to degrade extracellular proteins. The platforms open up new territory for targeted degradation therapies, on the...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
18:37 , Apr 4, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
18:24 , Mar 29, 2019 |  BC Week In Review  |  Clinical News

Arvinas brings its first PROTAC to the clinic

Arvinas said it has started dosing metastatic castration-resistant prostate cancer patients in a Phase I trial of ARV-110, an oral androgen receptor-targeted PROTAC. Preliminary data are expected next half. Arvinas Inc. (NASDAQ:ARVN) said it believes...